The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation

Cited by (614)

Items 301–400 of 614

1. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
   Ruizhe Wang, Yi Zhang, Fengping Shan · 2021 · International Immunopharmacology
2. Association between programmed death-1 pathway and major depression
   Kuan-Wei Huang, Tiao‐Lai Huang · 2023 · The World Journal of Biological Psychiatry
3. Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis
   Katrin Nitz, Joerg Herrmann, Amir Lerman, Esther Lutgens · 2024 · JACC Basic to Translational Science
4. Single peptides and combination modalities for triple negative breast cancer
   Atefeh P. Razazan, Javad Behravan · 2019 · Journal of Cellular Physiology
5. PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood
   Falk Wehrhan, Manuel Weber, Christoph Baran, Abbas Agaimy, Maike J. Büttner-Herold, Marco Rainer Kesting, Jutta Ries · 2020 · Journal of Cranio-Maxillofacial Surgery
6. Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
   Xiaoni Gao, Chengcheng Hong, Yang Xie, Xiangtai Zeng · 2023 · Frontiers in Oncology
7. ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies
   Akiko Matsumoto, Chiho Nakashima, Shinya H Kimura, Eizaburo Sueoka, Naoko Sueoka‐Aragane · 2021 · BMC Cancer
8. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status
   Sara Corvigno, Jared K. Burks, Wei Hu, Yanping Zhong, Nicholas B. Jennings, Nicole D. Fleming, Shannon Neville Westin, Bryan M. Fellman, Jinsong Liu, Anil K. Sood · 2021 · Journal of Cancer Research and Clinical Oncology
9. lncRNA EGFR-AS1 facilitates leiomyosarcoma progression and immune escape via the EGFR–MYC–PD-L1 axis
   Meiling Chen, Li Fan, Guangrong Huang, Zhi-feng Sun · 2022 · International Immunology
10. Programmed Cell Death Protein 1 (PD-1) in Relation to PANoptosis: Immune Pharmacological Targets for Management of Breast Adenocarcinoma
    Subarnarekha Maitra, Debarati Bhattacharya, Souvik Paul, Payel Ghosh Chowdhury, Dipanjan Mandal, Pallab Kanti Haldar, Ashok Kumar Balaraman, Asis Bala · 2023 · Endocrine Metabolic & Immune Disorders - Drug Targets
11. Immunotherapy of Clear-Cell Renal-Cell Carcinoma
    Sophie Grigolo, Luis Filgueira · 2024 · Cancers
12. Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer—A Systematic Review of the Current Status
    Stacy R. Bedore, Joshua van der Eerden, Faizan Boghani, Saloni J. Patel, Samer Yassin, Karina Aguilar, Vinata B. Lokeshwar · 2024 · International Journal of Molecular Sciences
13. New Developments and Therapeutic Drug Monitoring Options in Costimulatory Blockade in Solid Organ Transplantation: A Systematic Critical Review
    Gretchen N. de Graav, Suwasin Udomkarnjananun, Carla C. Baan, Marlies E. J. Reinders, Joke I. Roodnat, Brenda C. M. de Winter, Dennis Alexander Hesselink · 2024 · Therapeutic Drug Monitoring
14. T cell aging and exhaustion: Mechanisms and clinical implications
    Weiqi Zhang, Dejun Kong, Xiaohan Zhang, Lu Hu, Yeqi Nian, Zhongyang Shen · 2025 · Clinical Immunology
15. The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy
    Magdalena Lerch, Sudarshini Ramanathan · 2025 · Seminars in Immunology
16. Effect of dexmedetomidine on CD4+ T cells and programmed cell death protein-1 in postoperative analgesia: a prospective, randomized, controlled study
    Yulan Wang, Yishan Lei, Yanzheng Gu, Xiao-Qi Kong, Zhen BIAN, Fuhai Ji · 2021 · Minerva Anestesiologica
17. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
    Renrui Zou, Yaomin Wang, F. Ye, X. Zhang, Min Wang, Shiyun Cui · 2021 · Clinical & Translational Oncology
18. Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma
    Ping Liu, Ruoxu Chen, Xudong Zhang, Ruiting Fu, Tao Lin, Wei Jia · 2022 · BMC Genomics
19. The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
    Roberto Tamma, Giuseppe Ingravallo, Francesco Gaudio, Antonio d’Amati, Pierluigi Masciopinto, Emilio Bellitti, Loredana Lorusso, Tiziana Annese, Vincenzo Benagiano, Pellegrino Musto et al. · 2023 · Cancers
20. Immune paradigm and immunosuppressive dominance in the pathogenesis of major diseases of the modern man
    Kozlov Va · 2019 · Bulletin of Siberian Medicine
21. Recent advances regarding tumor microenvironment and immunotherapy in hepatocellular carcinoma
    Wei Qin, Zhenyu Cao, Siyuan Liu, Xun-Di Xu · 2020 · Hepatoma Research
22. Viruses, cancer and non-self recognition
    Monikaben Padariya, Umesh Kalathiya, Sara Mikac, Katarzyna Dziubek, Maria Camila Tovar-Fernandez, Ewa Maria Sroka, Robin Fåhræus, Alicja Sznarkowska · 2021 · Open Biology
23. Dual requirement for STAT signaling in dendritic cell immunobiology
    Gloria Donninelli, Isabella Sanseverino, Cristina Purificato, Sandra Gessani, Maria Cristina Gauzzi · 2017 · Immunobiology
24. Immunosenescence: Molecular Mechanisms, Diseases, and Therapeutic Innovations
    Ninghan Gong, Xiting Pan, Yusi Deng, Jiajia Che, Junhao Bao, Mengqi Wang, Chuan Xu, Xiaowei Liu, Ying Shi · 2025 · MedComm
25. Plasmablastic Lymphoma. A State-of-the-Art Review: Part 2-Focus on therapy
    Michele Bibas · 2024 · Mediterranean Journal of Hematology and Infectious Diseases
26. PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression
    Ioanna Ε. Stergiou, Kostas Palamaris, Georgia Levidou, Maria Tzimou, Stavros P. Papadakos, Georgios Mandrakis, Christos Masaoutis, Dimitra P. Rontogianni, Stamatios E Theocharis · 2024 · Biomedicines
27. Profiling of Tumor-Infiltrating Immune Cells and Their Impact on Survival in Glioblastoma Patients Undergoing Immunotherapy with Dendritic Cells
    Nataly Peres, Guilherme Alves Lepski, Carla Fogolin, Gabriela C. M. Evangelista, Elizabeth Alexandra Flatow, Jaqueline Vaz de Oliveira, Mariana Pereira Pinho, Patrícia Cruz Bergami-Santos, José Alexandre Marzagão Barbuto · 2024 · International Journal of Molecular Sciences
28. Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction
    Hanxun Wang, Lanlan Shen, Lu Chen, Yinli Gao, Lanyan Ma, Wenxiong Lian, Zhihao Zhang, Haihan Liu, Huali Yang, Jian Wang et al. · 2024 · European Journal of Medicinal Chemistry
29. Insight of immune checkpoint inhibitor related myocarditis
    Jin-Kui Pi, Xiao-ting Chen, Yanjing Zhang, Xue-mei Chen, Yin-Chan Wang, Jiayi Xu, Jin-han Zhou, Shuai-shuai Yu, Sisi Wu · 2024 · International Immunopharmacology
30. Programmed cell death protein receptor and ligands in haematological malignancies – Current status
    Marcin Sokołowski, Anna Sokołowska, Grzegorz J. Mazur, Aleksandra K. Butrym · 2019 · Critical Reviews in Oncology/Hematology
31. EWS-FLI1 low Ewing sarcoma cells demonstrate decreased susceptibility to T-cell-mediated tumor cell apoptosis
    Kelly M. Bailey, Claire M. Julian, Ariel N. Klinghoffer, Heather Bernard, Peter C. Lucas, Linda M. McAllister‐Lucas · 2019 · Oncotarget
32. CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
    Li Fu, Jingrong Li, Ke Yin, Juan Zhang, Zhenhu Li, Liang Lu, Yuanwu Bao, Zhen Qin, Yong Tang Zheng, Baotian Yang et al. · 2020 · Acta Pharmacologica Sinica
33. Current Therapy for Metastatic Urothelial Carcinoma
    Rosa Nadal, Joseph Clara, Begoña P. Valderrama, Joaquim Bellmunt B · 2021 · Hematology/Oncology Clinics of North America
34. PD-1 Suppresses the Osteogenic and Odontogenic Differentiation of Stem Cells from Dental Apical Papilla via Targeting SHP2/NF-κB Axis
    Na Li, Zehan Li, Lin Fu, Ming Yan, Yanqiu Wang, Jinhua Yu, Jintao Wu · 2022 · Stem Cells
35. Molecular Characterization of Lipoaspirates Used in Regenerative Head and Neck Surgery
    Kariem Sharaf, A Kleinsasser, Sabina Schwenk‐Zieger, Olivier Gires, Henrik Schinke, Vera Kohlbauer, Mark Jakob, Martin Canis, Frank Haubner · 2019 · JAMA Facial Plastic Surgery
36. A novel 68Ga-labeled cyclic peptide molecular probe based on the computer-aided design for noninvasive imaging of PD-L1 expression in tumors
    Shushan Ge, Bin Zhang, Jihui Li, Jinyu Shi, Tongtong Jia, Yan Wang, Zhengguo Chen, Shibiao Sang, Shengming Deng · 2023 · Bioorganic Chemistry
37. Foxp3+Helios+ regulatory T cells are associated with monocyte subsets and their PD-1 expression during acute HIV-1 infection
    Lifeng Liu, Qiuyue Zhang, Peng Chen, Na Guo, Aixin Song, Xiaojie Huang, Wei Xia, Li Li, Christiane Moog, Hao Wu et al. · 2019 · BMC Immunology
38. PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
    Katarzyna Malinowska, Andrzej Kowalski, Anna Merecz-Sadowska, Milena Paprocka-Zjawiona, Przemysław Sitarek, Tomasz Kowalczyk, Hanna Zielińska‐Bliźniewska · 2023 · Journal of Clinical Medicine
39. Process Development of a Macrocyclic Peptide Inhibitor of PD-L1
    Subha Mukherjee, Amanda Rogers, Gardner S. Creech, Chao Hang, Antonio Ramı́rez, Michael Dummeldinger, Shawn B. Brueggemeier, Claudio Mapelli, Serge Zaretsky, Masano Huang et al. · 2024 · The Journal of Organic Chemistry
40. Immunobiochemical Reconstruction of Influenza Lung Infection—Melanoma Skin Cancer Interactions
    Evgeni V. Nikolaev, Andrew Zloza, Eduardo D. Sontag · 2019 · Frontiers in Immunology
41. Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses
    Gabriela Green-Tripp, Callum Baird Nattress, Gunnel Halldén · 2022 · Frontiers in Molecular Biosciences
42. Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer
    Jingwen Hong, Guoxiang Guo, Suxin Wu, Shengzhe Lin, Zhifeng Zhou, Shuping Chen, Chunmei Ye, Jieyu Li, Wansong Lin, Yunbin Ye · 2022 · Journal of Leukocyte Biology
43. Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results
    Albert Qin, Chang‐Ru Wu, Ming‐Chih Ho, Chan‐Yen Tsai, Pei‐Jer Chen · 2023 · International Journal of Molecular Sciences
44. Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models
    Jordi Guiteras, Laura de Ramón, Elena Crespo, Núria Bolaños, Sílvia Barceló-Batllori, Laura Martínez-Valenzuela, Pere Fontova, Marta Jarque, Alba Torija, Oriol Bestard et al. · 2021 · International Journal of Molecular Sciences
45. IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
    Taylor A. Harper, Silvia M. Bacot, Christie Jane Fennell, Rebecca L. Matthews, Christina Zhu, Peng Yue, Alexander Benton, Devira Friedman, Adovi D. Akue, Mark A. KuKuruga et al. · 2021 · International Journal of Molecular Sciences
46. Immunoregulatory effects of RGMb in gut inflammation
    Magdiel Pérez-Cruz, Bettina Panagiota Iliopoulou, Katie Hsu, Hsin‐Hsu Wu, Tom Erkers, Kavya Swaminathan, Sai-Wen Tang, Cameron S. Bader, Neeraja Kambham, Bryan J. Xie et al. · 2022 · Frontiers in Immunology
47. Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma
    Xuyang Song, Robin Kate Kelley, MICHELLE L. GREEN, Nathan E. Standifer, KyoungSoo Lim, Diansong Zhou, James Dunyak, Alejandra Negro, John F. Kurland, Song Ren et al. · 2023 · Clinical Pharmacology & Therapeutics
48. Gender-related disparities in the frequencies of PD-1 and PD-L1 positive peripheral blood T and B lymphocytes in patients with alcohol-related liver disease: a single center pilot study
    Beata Kasztelan‐Szczerbińska, Katarzyna Adamczyk, Agata Surdacka, Jacek Roliński, Agata Michalak, Agnieszka A. Bojarska-Junak, Mariusz Szczerbiński, Halina Cichoż‐Lach · 2021 · PeerJ
49. LPS stimulates gingival fibroblasts to express PD-L1 via the p38 pathway under periodontal inflammatory conditions
    Kecong Zhou, Mengjun Sun, Yiru Xia, Yufeng Xie, Rong Shu · 2021 · Archives of Oral Biology
50. Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment
    Riley Rane, Fengqiao Li, Alexis Williams, A Jayadev, Nhan L. Tran, Jeffrey A. Winkles, Gloria B. Kim · 2025 · Frontiers in Immunology
51. CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management
    Yihao Liu, Yizhu Gao, Chenyu Huo, Tao Zeng, Wenjun Meng, Haoling Zhang, Qinqin He · 2026 · Translational Oncology
52. A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
    Daphne Day, John Park, Jermaine Ian George Coward, Ben Markman, Charlotte Lemech, James Chun-Yen Kuo, Amy Prawira, Michael Paul Brown, Sarwan K. Bishnoi, Dusan Kotasek et al. · 2023 · British Journal of Cancer
53. Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications
    Shi Zhou, Haijun Zhang · 2020 · Anti-Cancer Agents in Medicinal Chemistry
54. Interferon‑τ regulates the expression and function of bovine leukocyte antigen by downregulating bta‑miR‑204
    Xiaoyan Wang, Ting Yuan, Nannan Yin, Xiaofei Ma, Yaping Yang, Jing Yang, Aftab Shaukat, Ganzhen Deng · 2021 · Experimental and Therapeutic Medicine
55. Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
    Qin He, Yicheng Peng, Jie Sun, Jianxia Liu · 2021 · Frontiers in Oncology
56. Association of PD-L1 and p16 expression with clinicopathological parameters in oral cavity and oropharyngeal squamous cell carcinoma
    Richa Kareer, Sana Ahuja, Neena Chaudhary, Rashmi Arora · 2022 · Pathology - Research and Practice
57. Emerging and investigational targeted chemotherapy and immunotherapy agents for metastatic brain tumors
    J. Tanner McMahon, Razan R. Faraj, David Cory Adamson · 2020 · Expert Opinion on Investigational Drugs
58. Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression
    Nghiem Xuan Hoan, Phạm Thị Minh Huyền, Mai Thanh Binh, Ngo Tat Trung, Dao Phuong Giang, Bui Thuy Linh, Đặng Thị Ngọc Dung, Srinivas Reddy Pallerla, Peter G. Kremsner, Thirumalaisamy Palanichamy Velavan et al. · 2021 · Scientific Reports
59. Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials
    Saram Zafar, Rabbia Shehzadi, Hina Dawood, Moeez Maqbool, Azza Sarfraz, Zouina Sarfraz · 2024 · Therapeutic Advances in Medical Oncology
60. The role of immune checkpoint molecules in cancers
    Meilan Zhang, Junjie Xu, Zhaokuan Zheng, Zhiyun Guo, Hao Wang, Mingqing Zhou, Hailin Tang, Lewei Zhu · 2026 · Frontiers in Immunology
61. Nicotine treatment regulates PD-L1 and PD-L2 expression via inhibition of Akt pathway in HER2-type breast cancer cells
    Masanori A. Murayama, Erika Takada, Kenji Takai, Nagisa Nakata Arimitsu, Jun Shimizu, Suzuki Tomoko, Noboru Suzuki · 2022 · PLoS ONE
62. Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1
    Hue Tu Quach, Zhaohua Hou, Rebecca Y. Bellis, Jasmeen K. Saini, Alfredo Amador-Molina, Prasad S. Adusumilli, Yuquan Xiong · 2022 · Expert Opinion on Investigational Drugs
63. Data-based modeling of breast cancer and optimal therapy
    Yongzhen Pei, Siqi Han, Changguo Li, Jinzhi Lei, Fengxi Wen · 2023 · Journal of Theoretical Biology
64. Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
    Wei Zhang, Yongmin Liu, Dong Li, Shan Liu, Xiaojun Cai, Ji-Ying Tang, Zhigang Zuo, Xinhui Li, Yi Zhao · 2025 · Frontiers in Immunology
65. PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis
    Ting Xie, Ningzhi Wang, Guanghuai Yao, Songxin Xu, Dan Wang, Xinnong Liu, Liang‐Hao Hu, Guotao Lu, Ruihua Shi, Yanbing Ding · 2021 · Inflammation
66. IL-7-Treated Periodontal Ligament Cells Regulate Local Immune Homeostasis by Modulating Treg/Th17 Cell Polarization
    Xinyi Yu, Zhaoqiang Zhang, Jia-Chang Huang, Jiayu Lin, Xuepei Cai, Chufeng Liu · 2022 · Frontiers in Medicine
67. Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma
    Chandraditya Chakraborty, Srimoyee Mukherjee · 2022 · Current Oncology
68. Peptides targeting the BTLA-HVEM complex can modulate T cell immune response
    Karolina Wojciechowicz, Katarzyna Kuncewicz, Katarzyna Aleksandra Lisowska, Anna Wardowska, Marta Spodzieja · 2023 · European Journal of Pharmaceutical Sciences
69. Immunotherapy and Potential Predictive Biomarkers in the Treatment of Neuroendocrine Neoplasia
    Guanghui Xu, Yuhao Wang, Hushan Zhang, Xueke She, Jianjun Yang · 2020 · Future Oncology
70. Soluble programmed death‐1 (sPD‐1) as predictor of early surgical outcomes of paediatric cystic echinococcosis
    Eya Ben Salah, Wahiba Sakly, Coralie Barrera, Sana Mosbahi, Anne‐Pauline Bellanger, Rabeb Farhani, Amine Ksıa, Bruno Gottstein, Abdellatif Nouri, Hamouda Babba et al. · 2020 · Parasite Immunology
71. The dark side of immunotherapy: challenges facing the new hope in cancer treatment
    Eduard Teixidor, Joaquim Bosch‐Barrera · 2019 · Annals of Translational Medicine
72. Comprehensive analysis of macrophage-related multigene signature in the tumor microenvironment of head and neck squamous cancer
    Bo Lin, Hao Li, Tianwen Zhang, Xin Ye, Hongyu Yang, Yuehong Shen · 2021 · Aging
73. Combination of Ginsenoside Compound K and Anti-PD1 Inhibits Pancreatic Cancer by Activating CXCL13-CXCR5 Signaling Axis
    Shiyan Shang, Haixia Yang, Daidi Fan, Jianjun Deng · 2025 · Journal of Agricultural and Food Chemistry
74. Exosomes promote pre-metastatic niche formation in lung cancer
    Wentao Pan, Xue Gao, Xiaoyue Zhang, Yuwei Li, Qianqian Zhao, Dandan Wang, Miaoqing Zhao, Zhicheng Wu, Yueying Zhang · 2025 · Cancer Cell International
75. Plasmablastic Lymphoma
    Michele Bibas · 2023 · Elsevier eBooks
76. Blockade of BTLA alone or in combination with PD-1 restores the activation and proliferation of CD8+ T cells during in vitro infection with NCP BVDV
    Yu Liu, Zhi Zhao, Su Siyu, Yang Li, Nannan Chen, Linru He, Meiqi Dong, Bin Xu, Zecai Zhang, Yulong Zhou et al. · 2024 · Veterinary Microbiology
77. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy
    Yehao Yang, Ying Yu, Yun Fan, Hui Li · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
78. Type I Interferon Activates PD-1 Expression through Activation of the STAT1-IRF2 Pathway in Myeloid Cells
    Liyan Liang, Yingcui Yang, Kaidi Deng, Yanmin Wu, Yan Li, Liya Bai, Yinsong Wang, Chunwan Lu · 2024 · Cells
79. Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis
    Aaron C. Brown, José Quiroz, Devayu A. Parikh, Yafeng Li, Lukas Ritzer, Richard B. Rosen, Avnish A. Deobhakta · 2024 · BMC Ophthalmology
80. Residue-Specific Epitope Mapping of the PD-1/Nivolumab Interaction Using X-ray Footprinting Mass Spectrometry
    Line G. Kristensen, Sayan Gupta, Yan Chen, Christopher J. Petzold, Corie Y. Ralston · 2024 · Antibodies
81. The influence of immune checkpoint blockade on the outcomes of allogeneic hematopoietic stem cell transplantation
    Ya-Lei Hu, Yuxin Wang, Kaili Min, Huisheng Zhou, Xiaoning Gao · 2024 · Frontiers in Immunology
82. Genetic Blueprints in Lung Cancer: Foundations for Targeted Therapies
    Andra Dan, Livia Mălina Burtavel, Madalin-Codrut Coman, Ina Ofelia Focșa, Simona Gabriela Duta-Ion, Ioana Ruxandra Juganaru, Andra-Giorgiana Zaruha, Irina-Maria Strugari, Iulian Andrei Hotinceanu, Patricia-Christina Codreanu et al. · 2024 · Cancers
83. Immuno-comparative screening of adult-derived human liver stem/progenitor cells for immune-inflammatory-associated molecules
    Makram Merimi, Laurence Lagneaux, Catherine Anne Lombard, Douâa Moussa Agha, D Bron, Philippe Lewalle, Nathalie Meuleman, Mustapha Najimi, Etienne Marc Sokal, Mehdi Najar · 2021 · Inflammation Research
84. Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
    Anoushika Mehan, Michael Leonard Anthony, Pranoy Paul, Anjum Syed, Nilotpal Chowdhury, Shalinee Rao, Nuzhat Hussain, Bina Ravi · 2021 · Journal of Laboratory Physicians
85. Prognostic role of different PD-L1 expression patterns and tumor-infiltrating lymphocytes in high-grade serous ovarian cancer: a systematic review and meta-analysis
    Ye-Min Wang, Wei Cai, Qing-Ming Xue, Jinyao Zhang, Lv Zhou, Su-Yi Xiong, Huan Deng · 2023 · Frontiers in Immunology
86. The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer
    Wen-jie Guo, Sihan Liu, Xiaoli Zhang, Yating Chen, Ruo-Lan Qian, Ziyuan Zou, Xin Chen, Peng Luo · 2017 · Drug Design Development and Therapy
87. Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis
    Hongxia Cui, Yarong Li, Li Su, Guangxuan Liu · 2021 · Frontiers in Oncology
88. Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma
    Jia-Wei Luo, Yan-Hua Guo, Fengying Wu, Xuefei Li, Xue-Cheng Sun, Jia-Lu Wang, Caicun Zhou · 2021 · Disease Markers
89. Quiescence and aging of melanocyte stem cells and a novel association with programmed death-ligand 1
    Joseph W. Palmer, Kyrene M. Villavicencio, Misgana I. Idris, Ian J Baranyk, Nunaya Polycarp, Alex D. Dawson, Dominique Weddle, William J. Pavan, Fabian V. Filipp, Melissa L. Harris · 2024 · iScience
90. Potential therapeutic target in oncology: Protein palmitoylation (Review)
    Shiping Hao, Yongming Mei, Shaolin Chen, Jing Liu, Yao Zhang, Zhengfeng Zhu, Kangjia Zuo · 2025 · Oncology Reports
91. Glioma cells produce soluble PD-L1 via the Wnt/β-catenin signaling pathway to suppress CD8+ T cell activity
    Zihan Zhou, Yao Wang, Ying Wang, Chunhui Yuan, Junjian Lin, Xinbin Bai, Yunhao Chen, Man Hu, Xingchen Ding · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
92. Potential beneficial effects of PD-1/PD-L1 blockade in Alzheimer’s disease: a systematic review and meta-analysis of preclinical and clinical studies
    Ji-Young Yoon, Heonyoung Ha, Hyun Woo Lee, Seung-Yeon Kim, Yun Mi Yu, Heejung Chun · 2025 · Molecular Psychiatry
93. Exosomal PDL1 Suppresses the Anticancer Activity of CD8+ T Cells in Hepatocellular Carcinoma
    Qi Hu, Shuai Chen, Rilin Deng, Hongyu Deng, Mingjing Peng, Xiaohong Wang, Shun Deng, Jinfeng Wang, Biaoming Xu, Yan Xu et al. · 2024 · Analytical Cellular Pathology
94. Multiple machine learning-based integrations of multi-omics data to identify molecular subtypes and construct a prognostic model for HNSCC
    Xiaoqin Luo, Chao Li, Gang Qin · 2025 · Hereditas
95. Relationship between PD-L1 expression and [18F]FAPI versus [18F]FDG uptake on PET/CT in lung cancer
    Jingjie Qin, Chao Han, Haoqian Li, Zhendan Wang, Xudong Hu, Lanping Liu, Shouhui Zhu, Jingjing Zhao, Yuhong Sun, Yuchun Wei · 2025 · European Journal of Nuclear Medicine and Molecular Imaging
96. The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes
    Alev Ok Atılgan, Eda Yılmaz Akçay, Özlem Özen, A. Nihan Haberal Reyhan, Ali̇ Ayhan · 2022 · International Journal of Surgical Pathology
97. Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy
    Yan Zhang, Jiayan Gao, Yan He, Ziwei Qi, Long Qian, Wanpei Chen, Haiyan Xu, Yanhua Yue, Xunyuan Mao, Shuxin Guo et al. · 2023 · Journal of Immunology Research
98. Interleukin‐6 inhibitory effect of natural product naringenin compared to a synthesised monoclonal antibody against life‐threatening COVID‐19
    Melika AmeliMojarad, Mandana AmeliMojarad · 2023 · Reviews in Medical Virology
99. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes
    Alev Ok Atılgan, Merih Tepeoğlu, Özlem Özen, Nihan Haberal, Ali̇ Ayhan · 2023 · Annals of Diagnostic Pathology
100. Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity
     Noelia Silva-Pilipich, Ángela Covo-Vergara, Lucía Vanrell, Cristian Smerdou · 2023 · International review of cytology